Polynucleotides encoding heavy and light chains of antibodies to OPGL

What is this patent about?

’418 is related to the field of biotechnology and immunology, specifically focusing on the development of fully human monoclonal antibodies designed to treat bone-related pathologies. The invention addresses the biological imbalance between bone formation and resorption, a process regulated by the interaction between osteoprotegerin ligand (OPGL) and its receptor, ODAR. When OPGL over-stimulates this receptor, it triggers excessive osteoclast activity, leading to significant bone loss in conditions such as osteoporosis, rheumatoid arthritis, and Paget's disease.

The underlying idea behind ’418 is to disrupt the skeletal degradation cycle by utilizing a high-affinity, fully human antibody that mimics the natural regulatory function of osteoprotegerin. By specifically targeting and sequestering OPGL, the antibody prevents the ligand from docking with the ODAR receptor on the surface of bone-destroying cells. This molecular blockade effectively halts the signaling cascade required for osteoclast differentiation and activation, thereby restoring a more favorable equilibrium between bone deposition and destruction without the immunogenic risks associated with non-human or chimeric proteins.

The claims of ’418 focus on the genetic blueprints and methods for producing these therapeutic antibodies, specifically identifying the polynucleotide sequences that encode the heavy and light chain variable regions. The independent claims protect compositions comprising first and second polynucleotides that define the complementarity determining regions (CDRs) or the full variable amino acid sequences of SEQ ID NO: 13 and 14. These claims further encompass the expression vectors and host cells necessary to manufacture a functional antibody that inhibits the binding of human OPGL to its cognate receptor.

In practice, the invention is implemented by co-transfecting mammalian host cells, such as CHO cells, with expression vectors containing the specified heavy and light chain sequences. The resulting antibodies are secreted into the culture medium and purified through a series of chromatography steps to ensure high potency and safety. Once administered to a patient, the antibody circulates and binds to both soluble and membrane-bound OPGL with high specificity, demonstrating a dose-dependent inhibition of bone resorption markers like N-telopeptide, which provides a measurable clinical indicator of the drug's efficacy in stabilizing bone mass.

This approach differs from prior treatments, such as bisphosphonates or hormone therapies, by providing a highly targeted biological intervention that specifically interrupts the cytokine-driven pathway of osteoclastogenesis. Unlike earlier non-human antibodies, the fully human nature of this invention reduces the likelihood of neutralizing immune responses during chronic administration. Furthermore, the antibody's high affinity allows for significant suppression of bone resorption at relatively low concentrations, offering a potent biological alternative to traditional chemical agents for the long-term management of systemic and localized bone loss.